Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab + parsaclisib in relapsed/refractory B-cell malignancies
NCT04809467Phase 2Terminated
- Sponsor
- Incyte
- Start
- Sep 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of parsaclisib in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukemia (CLL), sponsored by Incyte. Started Sep 2021; status: terminated.
02
Drugs
parsaclisib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)follicular lymphoma (FL)marginal zone lymphoma (MZL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04809467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04809467.